Overview

Safety of Reduced Infliximab Infusion Time

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Remicade is a common medicine used for the treatment of inflammatory bowel disease. This medication is given as an intravenous infusion over 2 hours. Studies have suggested it is safe to give the infusion at a faster rate. The investigators would like to see if the infusion can be given over 1 hour. The investigators expect that increasing the rate of infusion WILL NOT lead to an increase in infusion reactions and will be just as safe and effective as the standard 2 hours dose.
Phase:
Phase 4
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Infliximab